Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.27.1 (RNase)
 16,360 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The influence of ribonuclease on the morphogenesis of experimental pancreatitis in the albino rats has been studied. The drug injected during edematous stage of pancreatitis caused some decrease of pancreatic enzymes level in the blood at hemorrhagic stage and its normalization at necrotic stage of pancreatitis. The development of hemorrhagic and necrotic stages of pancreatitis did not change under the influence of ribonuclease. The maturation of connective tissue of pseudocyst capsule was delayed and inflammatory infiltration of necrotic tissues and their elimination were increased under the influence of the drug. There were extensive tubular transformations of acini and early fibrosis and lipomatosis in the frontier zone. In the viable parts of pancreas moderate hypertrophy of exocrine pancreatocytes developed and chronic pancreatitis features appeared with use of ribonuclease.
 ...
PMID:[Ribonuclease in the experimental therapy of pancreatitis]. 261 83

In this study we evaluated some pathophysiological aspects of pancreatic and liver ribonucleases and alkaline deoxyribonuclease and their clinical usefulness in diagnosing pancreatic cancer. Pancreatic RNase was found to be a sensitive index of pancreatic malignancy; however it was not specific in distinguishing pancreatic malignancy from chronic pancreatitis or other pathologies. Liver RNase and alkaline DNase did not provide better results than pancreatic RNase. These three enzymes were found to be age-dependent and related to each other. Therefore serum nucleases are not useful for clinical purposes since they are influenced, at least in part, by different non-specific factors.
 ...
PMID:Ribonucleases and deoxyribonucleases in pancreatic cancer: clinical value and pathophysiological interrelationships. 320 63

In order to investigate the role of renal factors in affecting trypsinogen 1 metabolism and excretion in chronic pancreatic disease, serum immunoreactive trypsin (IRT), urinary IRT, gamma-glutamyltransferase (GGT), alpha-glucosidase (AGL) and RNase outputs and the molecular size distribution of serum and urine IRT were studied in 8 control subjects, 18 cases with pancreatic cancer, and 23 cases with chronic pancreatitis. Serum chromatography demonstrated that most immunoreactivity eluted as trypsinogen 1. Smaller amounts of immunoreactivity at higher molecular weights were also observed. Urine chromatography displayed both trypsinogen 1 and heavier molecular forms. An inverse linear correlation was noticed between creatinine clearance and serum trypsinogen 1 levels. Multiple regression analysis (urinary IRT output dependent and GGT, AGL, and RNase predictor variables) showed a significant linear correlation. RNase was found to be the most important parameter in explaining urinary IRT output. Mild variations in the glomerular function seem to be able to influence serum trypsinogen 1 levels. Urinary IRT excretion is principally explained by a disturbance in the tubular reabsorption of low molecular weight proteins, such as RNase.
 ...
PMID:Renal factors in serum trypsinogen 1 metabolism and excretion in chronic pancreatic disease. 336 41

Serum ribonuclease (RNase) and deoxyribonuclease (DNase) were investigated in 18 control subjects, and in 22 patients with pancreatic cancer, 13 with chronic pancreatitis and 29 with extrapancreatic diseases in order to assess their clinical usefulness in pancreatic cancer diagnosis and to evaluate whether modifications were consensual and/or age-related. Increased DNase and RNase values were found not only in a notable proportion of pancreatic cancer, but also in chronic pancreatitis and extra-pancreatic diseases. Thus the clinical value of both enzymes in pancreatic cancer diagnosis is negligible. DNase does not seem to be strictly age-dependent, whereas serum RNase does. Elevated levels of the two enzymes, when present, were consensual, suggesting that factors involved in such an increase were partially common to both.
 ...
PMID:Serum deoxyribonuclease and ribonuclease in pancreatic cancer and chronic pancreatitis. 408 85

In 116 subjects, serum ribonuclease (RNase) and ferritin were determined in order to evaluate whether their combined evaluation might improve the diagnostic accuracy of each test. Significantly higher levels were found in pancreatic cancer patients both for RNase and ferritin than in control subjects and chronic pancreatitis. Sensitivity and specificity in diagnosing pancreatic cancer were 86% and 46%, respectively for RNase; 76% and 65% for ferritin. One of the two tests was pathological in 100% of pancreatic cancer, with a specificity of 29.9%; both were pathological in 62.1%, with a specificity of 82.1%. The results emphasize the limits of the combined assessment of pancreatic cancer markers.
 ...
PMID:Combined evaluation of serum ribonuclease and ferritin: any advantages in pancreatic cancer diagnosis? 650 93

Urinary ribonuclease output and indices of renal tubular integrity were evaluated in control subjects and patients with pancreatic cancer, chronic pancreatitis and extrapancreatic diseases. The aim of the study was to ascertain the contribution to such diagnoses of ribonuclease determination in urine, and the possible influence of tubular damage on the extent of ribonuclease excretion. Information from the ribonuclease assay in urine offered no advantage over that obtained by the same determination in serum; tubular damage may contribution in some cases to an elevated ribonuclease excretion.
 ...
PMID:Urinary ribonuclease excretion in pancreatic disease. 663 38

Although serum ribonuclease (RNAase) activity (measured by Reddi's method [1]) was significantly higher in 24 patients with pancreatic carcinoma (mean 12.5 units) than in 93 control subjects (mean 5.0 units), 14 patients with chronic pancreatitis (mean 5.2 units) and 83 patients with other primary malignancies (mean 6.8 units), there was much overlap between the four groups and considerable (16.5%) inter-assay variation. Modification of the assay to eliminate a substrate inhibition effect gave acceptable inter-assay variation but abolished any significant difference between the four groups. Changes in serum RNAase activity did not reflect clinical changes in patients with pancreatic carcinoma followed serially during a trial of chemotherapy. The results indicate that serum RNAase is not a useful marker of pancreatic carcinoma.
 ...
PMID:Serum ribonuclease in the diagnosis of pancreatic carcinoma and in monitoring chemotherapy. 713 41

The possible role of poly(C)RNase serum activity and CEA serum level for early detection and differentiation of pancreatic carcinoma and its specificity and valuability were critically analyzed: Serum RNase (median, min-max) with polycytidin as substrate was determined in 13 "normal" patients (14.6 E/ml, 4.3--29.8 E/ml), 16 patients with pancreatic cancer (T3 or metastases) (17.6 E/ml, 6--49-9 E/ml), 15 patients with chronic pancreatitis (9.5 E/ml, 4.9--26.5 E/ml), 7 patients with acute pancreatitis (14.2 E/ml, 5.5--67.3 ng/ml), and 13 patients with other types of malignomas (15 E/ml, 4.3--42.5 E/ml). Serum CEA level was evaluated in 18 "normal" patients (1.15 ng/ml, 0--4.3 ng/ml), 12 patients with pancreatic carcinoma (T3 or metastases) (6.5 mg/ml, 2--456.5 ng/ml), 13 patients with chronic pancreatitis (2.3 ng/ml, 0--8.5 ng/ml), 8 patients with acute pancreatitis (2.7 ng/ml, 0.1--4.6 ng/ml) and 5 patients without operative verification of suspected pancreatic carcinoma (0.9 ng/ml, 0--1.7 ng/ml). The serum RNase activity in pancreatic cancer patients did not show any significant increase in comparison to the other groups, and these patients could not be distinguished from those with the other diseases when excluding other factors influencing serum RNase level such as: Renal insufficiency, nutrition, age, sex. Their CEA level was significantly higher in comparison to the other groups (p less than 0.05). Using 2.5 ng/ml as the limit, the sensitivity was found to be 80% (10/12 of pancreatic carcinomas positive) and the specificity being 70.5% (31/44 of other groups without malignant diseases negative). The presented study and data in the literature show that poly (C) RNase measurement is not useful in early detection of pancreatic carcinoma, but the CEA test could be helpful in the differential diagnosis of pancreatic diseases due to its specificity (70.5%) and seems to be valuable in detection of residual and in monitoring for recurrent pancreatic carcinoma in view of its sensitivity and correlation with the stage of cancer.
 ...
PMID:[The value of poly-C-specific serum ribonuclease and CEA in the diagnosis of pancreatic carcinoma (author's transl)]. 731 90

The so-called "plasma" ribonuclease (RNase), described as increased in most patients with pancreatic cancer, was studied in the blood of 92 subjects utilizing the method of Reddi and Holland, to evaluate its reliability in detecting pancreatic tumors. A significant increase of "plasma" RNase was found in pancreatic cancer (p less than 0.01) as compared with controls, non-calcifying chronic pancreatitis (p less than 0.01), calcifying chronic pancreatitis (p less than 0.01), and chronic recurrent pancreatitis (p less than 0.01). Nevertheless increased "plasma" RNase activity was also found in 18/43 patients with chronic pancreatitis, as well as in the majority of the non-pancreatic malignant tumors studied. Furthermore, in 2 out of 22 subjects with pancreatic cancer the enzyme activity was found to be normal. These data suggest that increased "plasma" RNase, although very frequent in pancreatic cancer, is not a marker of pancreatic malignancy.
 ...
PMID:"Plasma"-type ribonuclease in pancreatic cancer diagnosis: a critical appraisal. 734 12

The serum levels of a poly-[C]-specific acid ribonuclease (RNase) found in the pancreas was measured in 40 normal persons and 137 patients with pancreatic cancer, other cancers, obstructive jaundice, acute pancreatitis or chronic pancreatitis. Serum RNase increased by as much as 800 percent above normal in 69 percent of patients with pancreatic cancer. Analysis of the serum isoenzymes of RNase by isoelectric focusing did not reveal any unique RNases produced by the tumours. In contrast, serum RNase rose in only 8 percent of patients with other cancers, 11 percent of other patients with obstructive jaundice and in no patients with chronic pancreatitis. These data suggest that the finding of increased serum RNase is of adjunctive value inthe diagnosis of pancreatic carcinoma and may be particularly helpful in distinguishing it from other causes of biliary obstruction and from chronic pancreatitis.
 ...
PMID:Sensitivity and specificity of serum ribonuclease in the diagnosis of pancreatic cancer. 735 Aug 42


<< Previous 1 2 3 Next >>